His resignation, effective January 9, 2009, follows an 11-year career with Acusphere, in which he oversaw the company’s clinical trials for its lead product candidate, Imagify for injectable suspension, a cardiovascular drug for the detection of coronary artery disease.
Sherri Oberg, president and CEO of Acusphere, said: “Rick has made many significant contributions to Acusphere’s success over the past 11 years, and we greatly appreciate his commitment to seeing this project through to its final stage. We wish him well in his next venture.”